Private company

THERALINK TECHNOLOGIES, INC.

THERALINK TECHNOLOGIES, INC. is an American pharmaceutical preparations company based in Golden.1

Last updated Oct 20, 2026.

Overview

  • IndustryPharmaceutical Preparations1
  • HeadquartersBaton Rouge, Louisiana1
  • Incorporated inNV2
  • Business address8000 Innovation Park, Dr, Baton Rouge, Baton Rouge, La 708202
  • Filer categoryNon-accelerated filer, Smaller reporting company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

Pan-Tumor Assay 2.0 to support the treatment of colorectal, prostate, pancreatic, lung, and other solid tumor cancer indications.3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2023

79.2%Gross margin4
-1479.8%Operating margin4
-5093.6%Net margin4
6.8%Revenue growth, 20234
-$5.9MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2023

  • Cost of revenue1¢$126.2K
  • Selling, general and admin1¢$125.0K
  • Interest99¢$16.9M

Out of $606.8K in revenue.4 The company lost money this year.

Financial statements

Revenue564$606.8K in 2023+235% since 2020
0$200.0K$400.0K$600.0K$800.0K2020: $181.2K$181.2K20202021: $505.6K$505.6K2021+179%2022: $567.9K$567.9K2022+12%2023: $606.8K$606.8K2023+7%
Gross profit564$480.6K in 2023+274% since 2020
0$200.0K$400.0K$600.0K2020: $128.6K$128.6K20202021: $388.1K$388.1K2021+202%2022: $343.0K$343.0K2022−12%2023: $480.6K$480.6K2023+40%
Operating income78564-$9.0M in 2023+265% since 2017
-$15.0M-$10.0M-$5.0M02017: -$2.5M-$2.5M20172018: -$1.8M-$1.8M2018−28%2019: -$1.8M-$1.8M2019−1%2020: -$3.4M-$3.4M2020+90%2021: -$5.6M-$5.6M2021+66%2022: -$11.6M-$11.6M2022+109%2023: -$9.0M-$9.0M2023−23%
Net income78564-$30.9M in 2023+51% since 2017
-$40.0M-$30.0M-$20.0M-$10.0M0$10.0M2017: -$20.5M-$20.5M20172018: $6.5M$6.5M20182019: -$9.4M-$9.4M20192020: -$3.2M-$3.2M2020−66%2021: -$5.5M-$5.5M2021+73%2022: -$12.7M-$12.7M2022+133%2023: -$30.9M-$30.9M2023+143%
Fiscal year2017201820192020202120222023
Revenue$181.2K5$505.6K6$567.9K4$606.8K4
Cost of revenue$52.6K5$117.5K6$224.9K4$126.2K4
Gross profit$128.6K5$388.1K6$343.0K4$480.6K4
Research and development$103.9K7$204.6K8$166.7K8
Selling, general and admin$150.0K4$125.0K4
Operating expenses$12.0M4$9.5M4
Operating income-$2.5M7-$1.8M8-$1.8M8-$3.4M5-$5.6M6-$11.6M4-$9.0M4
Interest$1.2M7$2.1M8$1.8M8$31.2K5$121.1K6$1.1M4$16.9M4
Income tax
Net income-$20.5M7$6.5M8-$9.4M8-$3.2M5-$5.5M6-$12.7M4-$30.9M4
Earnings per share-$0.167$20.668-$19.008$0.006$0.004-$0.014
Earnings per share (diluted)-$0.167$9.098-$19.008$0.004-$0.014
Shares (weighted, basic)5.9B shares46.2B shares4
Shares (weighted, diluted)5.9B shares46.2B shares4

Compare THERALINK TECHNOLOGIES, INC. with another company

What it owns

What THERALINK TECHNOLOGIES, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$76.5K4 Sep 30, 2023$68.5K4 Sep 30, 2022+11.6%
Furniture and fixtures$24.6K4 Sep 30, 2023$24.6K4 Sep 30, 20220%
Leasehold improvements$353.8K4 Sep 30, 2023$353.8K4 Sep 30, 20220%
Property and equipment, before depreciation$968.6K4 Sep 30, 2023$1.0M4 Sep 30, 2022−7.2%
Accumulated depreciation$520.1K4 Sep 30, 2023$357.8K4 Sep 30, 2022+45.4%
Property and equipment, net$448.5K4 Sep 30, 2023$686.1K4 Sep 30, 2022−34.6%
Finance-lease assets$19.0K4 Sep 30, 2023$65.0K4 Sep 30, 2022−70.8%
Operating-lease assets (leased space)$1.1M4 Sep 30, 2023$1.2M4 Sep 30, 2022−4.4%

Investments

ItemLatestA year beforeChange
Marketable securities, current$8004 Sep 30, 2023$3.7K4 Sep 30, 2022−78.4%

Leadership

Who has led THERALINK TECHNOLOGIES, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Cameron Durrant2011–2013
  2. Constantin Dietrich2015
  3. Jonathan Frederick Head2016–2019
  4. Brian Gill Barnett2019
  5. Andrew Albert Kucharchuk2020
  6. Michael I. Ruxin2020–2022

Chair

  1. Jeffrey Busch2022

President

  1. Shawn Perger2006
  2. Cameron Durrant2011–2013
  3. Andrew Albert Kucharchuk2016
  4. Faith Zaslavsky2023

Chief financial officer

  1. David L. Tousley2010–2011
  2. Cameron Durrant2013
  3. Andrew Albert Kucharchuk2016–2020
  4. Thomas E. Chilcott Iii.2020–2022

Chief operating officer

  1. Carlos Fernando Alaman Volnie2017
  2. Faith Zaslavsky2023
2010201520202025
Board members and other officers (19)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorMick Ruxin named Dec 14, 202239
  • DirectorMatthew W. Schwartz, MD named Dec 14, 202239

Former names

  • OncBioMune Pharmaceuticals, IncSep 8, 2015 to Sep 22, 20202
  • QUINT MEDIA INC.Aug 8, 2013 to Aug 6, 20152
  • PediatRx Inc.Jan 6, 2011 to Aug 6, 20132
  • Striker Energy CorpMay 5, 2006 to Dec 28, 20102

Timeline

  1. Mar 6, 20248-K Debt or obligation accelerated40
  2. Nov 28, 20238-K Other events41
  3. Jun 29, 20238-K Executive or director change; Regulation FD disclosure42
  4. May 26, 20238-K Entered a material agreement; Other events43
  5. May 11, 20238-K Executive or director change44
  6. Feb 1, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares45
  7. Dec 9, 20228-K Executive or director change; Regulation FD disclosure46
  8. Dec 1, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares47
  9. Sep 16, 20228-K Entered a material agreement; New debt or obligation48
  10. Jul 12, 20228-K Bylaws or fiscal year changed; Shareholder vote49
  11. Jul 7, 20228-K Bylaws or fiscal year changed; Shareholder vote50
  12. Apr 6, 20228-K Executive or director change51
  13. Jun 18, 2020New chief executive Michael I. Ruxin becomes CEO14
  14. May 8, 2020New chief executive Andrew Albert Kucharchuk becomes CEO13
  15. Jan 7, 2019New chief executive Brian Gill Barnett becomes CEO15
  16. Feb 4, 2016New chief executive Jonathan Frederick Head becomes CEO16
  17. Mar 18, 2015New chief executive Constantin Dietrich becomes CEO17
  18. Feb 11, 2011New chief executive Cameron Durrant becomes CEO18

Filings

51 filings to the SEC since October 2021: 4 annual reports, 7 quarterly reports, 16 major events, 12 insider forms, 1 private raises, 11 other. The latest 20:

  1. May 15, 202415-12G EDGAR
  2. Mar 6, 20248-K EDGAR
  3. Feb 20, 202410-Q EDGAR
  4. Feb 15, 202410-K/A EDGAR
  5. Feb 15, 2024NT 10-Q EDGAR
  6. Feb 2, 20244 EDGAR
  7. Jan 26, 20244 EDGAR
  8. Jan 26, 20244 EDGAR
  9. Jan 5, 202410-K EDGAR
  10. Dec 29, 2023NT 10-K EDGAR
  11. Dec 19, 20233 EDGAR
  12. Nov 28, 20238-K EDGAR
  13. Aug 21, 202310-Q EDGAR
  14. Aug 15, 2023NT 10-Q EDGAR
  15. Jun 29, 20238-K EDGAR
  16. May 26, 2023425 EDGAR
  17. May 26, 20238-K EDGAR
  18. May 15, 202310-Q EDGAR
  19. May 11, 20238-K EDGAR
  20. Feb 21, 202310-Q EDGAR

The 51 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 29, 2022Filed a private offering of debt Form D: $3.4 million offered in all Form D

SEC filer profile

How THERALINK TECHNOLOGIES, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARTHERALINK TECHNOLOGIES, INC.1
  • CIK0001362703
  • Employer ID (EIN)20-25908101
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inNevada1
  • Fiscal year endsSeptember 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address8000 Innovation Park, Dr, Baton Rouge, Baton Rouge, LA 708201
  • Phone225-578-75551
  • Shares outstanding6,151,499,919 as of Feb 20, 202411
  • Public float$2.5M as of Mar 31, 202352
  • On EDGAR sinceMay 5, 20061
  • Filings402 in all: 8-K (134), 4 (48), 10-Q (47), 3 (31), NT 10-Q (19), 10-K (16), SC 13D (11), SC 13D/A (9)1
    All 37 form types

    D (8), 4/A (7), 8-K/A (7), NT 10-K (7), UPLOAD (7), 10QSB (6), CORRESP (5), DEF 14C (4), POS AM (4), PRE 14C (4), 424B3 (3), CT ORDER (3), EFFECT (3), 10KSB (2), 3/A (2), SC 14F1 (2), 10-K/A (1), 10-Q/A (1), 10SB12G (1), 15-12G (1), 425 (1), DEFM14C (1), NT 10-K/A (1), PREM14C (1), PRER14C (1), REGDEX (1), S-1 (1), SC 13G (1), SC 13G/A (1)

  • Latest filingsAnnual report (10-K) Jan 5, 2024
    Quarterly report (10-Q) Feb 20, 2024
    Latest 8-K (8-K) Mar 6, 2024

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
    SEC EDGAROther events
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52